Ontuxizumab

Modify Date: 2024-01-15 19:27:08

Ontuxizumab structure	Common Name	Ontuxizumab
	CAS Number	946415-62-9	Molecular Weight	N/A
	Density	N/A	Boiling Point	N/A
	Molecular Formula	N/A	Melting Point	N/A
	MSDS	N/A	Flash Point	N/A

Use of Ontuxizumab

Ontuxizumab (MORAb-004) is a humanized IgG1/κ anti-endosialin (TEM-1 or CD248) monoclonal antibody with antitumor effects. Ontuxizumab can be used for the research of cancer[1].

Name	Ontuxizumab

Description	Ontuxizumab (MORAb-004) is a humanized IgG1/κ anti-endosialin (TEM-1 or CD248) monoclonal antibody with antitumor effects. Ontuxizumab can be used for the research of cancer[1].
Related Catalog	Research Areas >> Cancer Signaling Pathways >> Others >> Others
In Vitro	Ontuxizumab (0-100 μg/mL；12 小时) 诱导 CD248 内化并剂量依赖性地降低了 46% 的人周皮细胞表面的 CD248[1]。
In Vivo	Ontuxizumab (50 mg/kg；静脉注射，每天 5 次，连续 5 天) 在人 CD248 敲入小鼠显示抗肿瘤作用[1]。 Animal Model: Human CD248 knock-in mice[1] Dosage: 50 mg/kg Administration: Intravenous injection via tail vein; 50 mg/kg, 5 doses daily for 5 consecutive days Result: Reduced tumor growth with a lower level of CD248 and α-SMA on neovasculature pericytes.
References	[1]. Rybinski K, et al. Targeting endosialin/CD248 through antibody-mediated internalization results in impaired pericyte maturation and dysfunctional tumor microvasculature. Oncotarget. 2015 Sep 22;6(28):25429-40.

No Any Chemical & Physical Properties